The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study.

The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study. - The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007234

Enrollment

Registered

2012-02-06

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patient

Interventions

Medication, Blood sampling for PK/PD

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with informed consent. 2) Age:over 20 years ( at the time the informed consent form is signed ) 3) Gender: Male or female, In patients or Out patients. 4) Patients with regularly hemodialyzed. 5) Patients without influenza virus.

Exclusion criteria

Exclusion criteria: 1) History of hypersensitivity, allergy or serious adverse drug event caused by oseltamivir phosphate, zanamivir hydrate, peramivir hydrate or raninanivir. 2)Patient with contraindications of 1) drugs. 3)Hepatic disorder. 4) Women who are pregnant or suspected to be pregnant and women who are breast-feeding. 5) Any other patients whose condition is inappropriate for the evaluation of this clinical study as judged by the investigator.

Design outcomes

Primary

Measure	Time frame
To evaluate the appropriate usage/dosage of peramivir.	—

Countries

Japan

Contacts

Public ContactTakashi Akiba

Tokyo Women's Medical University Hospital Department of Bloods Purification, Kidney Center

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026